Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

CervoMed (CRVO) Shares Outstanding (Weighted Average) (2022 - 2025)

CervoMed's Shares Outstanding (Weighted Average) history spans 9 years, with the latest figure at $9.3 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 17.69% year-over-year to $9.3 million; the TTM value through Sep 2025 reached $9.3 million, up 17.69%, while the annual FY2024 figure was $8.1 million, 203.34% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $9.3 million at CervoMed, up from $9.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $9.3 million in Q3 2025 and bottomed at $518140.0 in Q4 2022.
  • The 4-year median for Shares Outstanding (Weighted Average) is $4.4 million (2023), against an average of $4.8 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) tumbled 74.59% in 2023 before it skyrocketed 1335.26% in 2024.
  • A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $518140.0 in 2022, then soared by 413.65% to $2.7 million in 2023, then skyrocketed by 203.34% to $8.1 million in 2024, then increased by 14.61% to $9.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRVO's Shares Outstanding (Weighted Average) are $9.3 million (Q3 2025), $9.0 million (Q2 2025), and $8.7 million (Q1 2025).